Neuland Laboratories Ltd. Corporate Filings & Announcements

Pharmaceuticals company Neuland Laboratories announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: Total Income: Rs 335.8 crore vs. Rs 390.4 crore — down 14.0% EBITDA: Rs 58.2 crore vs. Rs 112.2 crore — down 48.1% EBITDA Margin %: 17.3% vs. 28.7% — contracted by 1140 bps PAT: Rs 27.7 crore vs. Rs 67.6 crore — down 59.0% PAT Margin %: 8.3% vs. 17.3% — contracted by 900 bps EPS (Basic): Rs 21.6 vs. Rs 52.7 — down 59.0% FY25 Financial Highlights: Total Income: Rs 1,497.3 crore vs. Rs 1,571.1 crore — down 4.7% EBITDA: Rs 342.8 crore vs. Rs 474.5 crore — down 27.7% EBITDA Margin %: 22.9% vs. 30.2% — contracted by 730 bps PAT: Rs 259.4 crore vs. Rs 299.6 crore — down 13.4% PAT Margin %: 17.3% vs. 19.1% — contracted by 180 bps EPS (Basic): Rs 202.2 vs. Rs 233.5 — down 13.4% Commenting on the performance Sucheth Davuluri, Vice-Chairman and Chief Executive Officer of the Company said, “We saw marginal decrease in topline in FY25 as compared to FY24. which is further reflected in terms of the decline in operating margins. Nevertheless, these results are in line with our initial outlook at the start of the year regarding our expectations for FY25. During the course of the year we have committed to making investments which will significantly drive our growth in the medium and long term. Neuland continues to be recognized for its capabilities and quality track record, and we have good visibility on short and long term growth” In addition, Saharsh Davuluri, Vice Chairman and Managing Director, Neuland Laboratories added “The CMS revenues of Rs. 637 crores were largely driven by molecules in the commercial segment. Even though the revenues have declined this year, we continue to see good traction in business from a wider range of customers Our peptide investment plan is on track. We continue to garner more projects in this space which further validates our excitement about the opportunities that the segment holds. At an overall level, we have molecules in our portfolio which are currently at the take off stage, therefore we expect our growth trajectory to resume in FY26.” Result PDF

29.06% Fall from 52W High

High volume+gain today

Neuland Laboratories Ltd. Corporate Filings & Announcements

Latest corporate announcements and filings from Neuland Laboratories Ltd. on BSE